Ask AI
ADA 2026 obesity studies

CE / CME

Translating Emerging Obesity Evidence Into Clinical Action: Highlights From ADA 2026

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: July 21, 2026

Expiration: July 20, 2027

Activity

Progress
1 2 3
Course Completed

References

  1. Jastreboff A. Results of first phase 3 study of retatrutide, a GIP, GLP-1, and glucagon receptor agonist in patients with obesity (TRIUMPH-1). Presented at: American Diabetes Association’s 2026 Scientific Sessions; June 5-8, 2026.
  2. Wysham C, Davies MJ, Lee CJ, et al. Orforglipron and markers of insulin sensitivity and beta-cell function by prediabetes status in adults with obesity: a post hoc analysis of the ATTAIN-1 trial. Presented at: American Diabetes Association’s 2026 Scientific Sessions; June 5-8, 2026. Abstract 1666-P.
  3. Rubino D, Wilson L, Traina A, et al. Cardiometabolic effects of semaglutide in OASIS 4 participants by BMI class. Presented at: American Diabetes Association’s 2026 Scientific Sessions; June 5-8, 2026. Abstract 2838-LB.
  4. Bak N, Alex M, Fuglsang SA, et al. Effects of CagriSema on appetite and function brain activity in people with overweight/obesity. Presented at: American Diabetes Association’s 2026 Scientific Sessions; June 5-8, 2026. Abstract 1035-OR.
  5. Katsi V, Koutsopoulos G, Fragoulis C, et al. Retatrutide: a game changer in obesity pharmacotherapy. Biomolecules. 2025;15:796.
  6. Tirzepatide [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2026.
  7. Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;[Epub ahead of print].
  8. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393:1796-1806.
  9. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med. 2025;393:1077-1087.
  10. Semaglutide [prescribing information]. Plainsboro, NJ: Novo Nordisk; 2026.
  11. Farr OM, Li CR, Mantzoros CS. Central nervous system regulation of eating: insights from human brain imaging. Metabolism. 2016;65:699-713.
  12. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;393:635-647.